Early findings show efficacy of water vapor therapy for treating intermediate-risk prostate cancer with minimal procedural ...

Minimally invasive transperineal laser ablation (TPLA) of the prostate appears effective for benign prostatic hyperplasia (BPH), according to a review published online Sept. 21 in Therapeutic Advances ...

(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...

From steam injections to drug-coated balloons, the options for treating an enlarged prostate are growing fast.

Patient outcomes were assessed 2 years after treatment with the Optilume BPH Catheter System, a minimally invasive surgical therapy for the treatment of lower urinary tract symptoms (LUTS) due to ...

The study will enrol up to 40 participants across a maximum of five clinical sites in the US.

A new final guidance from the US Food and Drug Administration (FDA) addresses clinical testing and clinical data collection to support marketing authorizations for high intensity ultrasound systems to ...

For an estimated one in two men aged 51 to 60, benign prostatic hyperplasia (BPH), or an enlarged prostate, is the number one reason they visit the urologist. Risk factors for BPH include aging, ...

AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

NEW BERN, N.C. (WNCT) — The Urology team at CarolinaEast Health System announced they are offering A quablation therapy and have completed their 100th treatment. A quablation therapy treats the lower ...